Literature DB >> 23296299

Glomerular disease in 2012: more mechanistic insights, but translational progress is slow.

Jeffrey B Kopp1.   

Abstract

The year 2012 brought a continued harvest of new findings of relevance to glomerular biology and disease. Progress in glomerular disease has continued, although our understanding of disease processes continues to extend much further than our ability to intervene effectively.

Entities:  

Mesh：

Year:  2013        PMID： 23296299     DOI： 10.1038/nrneph.2012.288

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

Authors:  Edmund J Lewis; Julia B Lewis; Tom Greene; Lawrence G Hunsicker; Tomas Berl; Marc A Pohl; Dick de Zeeuw; Hiddo Lambers Heerspink; Richard D Rohde; Robert C Atkins; Anne T Reutens; David K Packham; Itamar Raz
Journal:  Am J Kidney Dis       Date:  2011-08-26       Impact factor: 8.860

3.  Pyridorin in type 2 diabetic nephropathy.

Authors:  Edmund J Lewis; Tom Greene; Samuel Spitalewiz; Samuel Blumenthal; Tomas Berl; Lawrence G Hunsicker; Marc A Pohl; Richard D Rohde; Itamar Raz; Yair Yerushalmy; Yoram Yagil; Tommy Herskovits; Robert C Atkins; Anne T Reutens; David K Packham; Julia B Lewis
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

4.  Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

Authors:  David K Packham; Rory Wolfe; Anne T Reutens; Tomas Berl; Hiddo Lambers Heerspink; Richard Rohde; Sara Ivory; Julia Lewis; Itamar Raz; Thomas B Wiegmann; Juliana C N Chan; Dick de Zeeuw; Edmund J Lewis; Robert C Atkins
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

5.  Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.

Authors:  Giovanni Gambaro; Ida Kinalska; Adrian Oksa; Peter Pont'uch; Miluse Hertlová; Jindrich Olsovsky; Jacek Manitius; Domenico Fedele; Stanislaw Czekalski; Jindriska Perusicová; Jan Skrha; Jan Taton; Wladyslaw Grzeszczak; Gaetano Crepaldi
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

6.  Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy.

Authors:  Aki Kuroki; Masayuki Iyoda; Takanori Shibata; Tetsuzo Sugisaki
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

7.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

9.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Hanna Debiec; Colin D Short; Timotheé Pellé; Robert Kleta; Peter W Mathieson; Pierre Ronco; Paul E Brenchley; Jack F Wetzels
Journal:  J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 10.121

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.